Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Net Income towards Common Stockholders (2016 - 2026)

Organogenesis Holdings has reported Net Income towards Common Stockholders over the past 10 years, most recently at $35.1 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 497.82% year-over-year to $35.1 million; the TTM value through Dec 2025 reached $15.9 million, up 1792.0%, while the annual FY2025 figure was $20.0 million, 2236.82% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was $35.1 million at Organogenesis Holdings, up from $14.5 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $51.0 million in Q4 2021 and troughed at -$21.6 million in Q1 2025.
  • A 5-year average of $6.6 million and a median of $5.6 million in 2023 define the central range for Net Income towards Common Stockholders.
  • Biggest five-year swings in Net Income towards Common Stockholders: surged 1373.02% in 2023 and later plummeted 928.14% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at $51.0 million in 2021, then plummeted by 81.44% to $9.5 million in 2022, then tumbled by 106.0% to -$568000.0 in 2023, then skyrocketed by 1134.33% to $5.9 million in 2024, then surged by 497.82% to $35.1 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for ORGO at $35.1 million in Q4 2025, $14.5 million in Q3 2025, and -$12.2 million in Q2 2025.